Fine-tuning T cell function through engineered orthogonal chimeric cytokine receptors
Crossref DOI link: https://doi.org/10.1038/s41422-022-00715-w
Published Online: 2022-08-24
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kishton, Rigel J.
Restifo, Nicholas P.
Text and Data Mining valid from 2022-08-24
Version of Record valid from 2022-08-24
Article History
First Online: 24 August 2022
COMPETING INTERESTS
: R.J.K. and N.P.R. receive compensation and own equity in Lyell Immunopharma.